Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2. [electronic resource]
Producer: 19881216Description: 457-72 p. digitalISSN:- 0732-6580
- Antibodies, Monoclonal
- Antigens, Surface -- analysis
- Cyclophosphamide -- administration & dosage
- Cytotoxicity, Immunologic -- drug effects
- Drug Evaluation
- Drug Therapy, Combination
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Immunity, Cellular -- drug effects
- Injections, Subcutaneous
- Interleukin-2 -- administration & dosage
- Male
- Middle Aged
- Mitogens
- Neoplasms -- therapy
- Random Allocation
- Recombinant Proteins -- administration & dosage
- T-Lymphocytes -- drug effects
- Time Factors
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.